Please login to the form below

Not currently logged in
Email:
Password:

EGFR inhibitor

This page shows the latest EGFR inhibitor news and features for those working in and with pharma, biotech and healthcare.

AZ’s immuno-oncology combo fails another lung cancer trial

AZ’s immuno-oncology combo fails another lung cancer trial

There is no doubt, however, that the study raises another question mark over the role of CTLA4 inhibitor tremelimumab. ... There was better news for AZ in cancer last week, after the company picked up FDA approval for its EGFR inhibitor Tagrisso

Latest news

  • AZ makes case for first-line Tagrisso therapy in lung cancer AZ makes case for first-line Tagrisso therapy in lung cancer

    AstraZeneca says that new data from its FLAURA trial of EGFR inhibitor Tagrisso makes a compelling argument that the drug should be use ahead of other dugs in the class in ... using Tagrisso (osimertinib) first-line in EGFR-mutated non-small cell lung

  • Reviews start for Pfizer’s wildcard lung cancer drug dacomitinib Reviews start for Pfizer’s wildcard lung cancer drug dacomitinib

    The EMA and FDA have started the clock ticking on their appraisals for dacomitinib, a pan-EGFR tyrosine kinase inhibitor, for the first-line treatment of patients with locally advanced or ... September. The study showed that dacomitinib improved median

  • Lilly drops Hanmi-partnered arthritis drug Lilly drops Hanmi-partnered arthritis drug

    Lilly drops Hanmi-partnered arthritis drug. Concludes that its BTK inhibitor is likely to be clinically ineffective. ... Boehringer handed back rights to EGFR inhibitor olmutinib (HM61713) after serious side effects were seen in phase III trials.

  • Clock starts ticking on AZ’s first-line lung cancer filing in US Clock starts ticking on AZ’s first-line lung cancer filing in US

    Third-generation EGFR inhibitor Tagrisso (osimertinib) is already approved as a follow-up to older drugs in the class, including AZ’s own Iressa (gefitinib) product and Roche's Tarceva (erlotinib), ... were updated to include the use of Tagrisso in the

  • AZ speeds first-line lung cancer filing for Tagrisso to EMA AZ speeds first-line lung cancer filing for Tagrisso to EMA

    Just a few weeks after reporting positive phase III results, AstraZeneca has filed Tagrisso with the EMA as a first-line treatment for patients with EGFR-positive non-small cell lung ... AZ describes Tagrisso as a third-generation EGFR inhibitor, with

More from news
Approximately 1 fully matching, plus 51 partially matching documents found.

Latest Intelligence

  • Interview: AstraZeneca's Susan Galbraith Interview: AstraZeneca's Susan Galbraith

    EGFR-TK) inhibitor, which has so far been approved in non-small cell lung cancer, albeit after a much-delayed, stop-start regulatory journey. ... If approved, the drug would complement AZ's other NSCLC drug, Iressa, which is approved in NSCLC patients

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Apex.co.uk Conferences, Events and Exhibition Stands

Apex.co.uk is one of the UK’s leading event and exhibition agencies, specialising in healthcare. We understand your communication goals, whether...

Latest intelligence

No Voice, No Choice
Adelphi Research UK’s insights help to campaign for change in the Mental Health Act...
Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...

Infographics